Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Streamlining first-in-human PET radiopharmaceutical development: FDA's evolving stance on preclinical dosimetry

American Journal of Nuclear Medicine and Molecular Imaging(2025)10.62347/kjlm2547Source: DataRank Database

Streamlining first-in-human PET radiopharmaceutical development: FDA's evolving stance on preclinical dosimetry is a research paper published in American Journal of Nuclear Medicine and Molecular Imaging (2025). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)OA: bronzeTopics (8)IDs (PubMed, PMC)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (1)

Taoqian Zhao

Live enrichment

PubMed:40980737 PMC:PMC12444401

NIMH NIH HHS

Grant: R01 MH128705

bronze

publisherhttps://doi.org/10.62347/kjlm2547

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12444401/

Keywords

RadiopharmaceuticalsNuclear MedicineDosimetryPET imagingPreclinical StudiesFda GuidanceAdministered ActivityFirst-in-human Study